Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes

BACKGROUND: Patients with multiple sclerosis (MS) on some disease modifying therapies (DMTs), particularly anti-CD20 and sphingosine-1-phosphate (S1P) modulators, are at increased risk of severe Coronavirus Disease 19 (COVID-19) and death. COVID-19 vaccinations are effective in preventing infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Holroyd, Kathryn B., Healy, Brian C., Conway, Sarah, Houtchens, Maria, Bakshi, Rohit, Bhattacharyya, Shamik, Bose, Gauruv, Galetta, Kristin, Kaplan, Tamara, Severson, Christopher, Singhal, Tarun, Stazzone, Lynn, Zurawski, Jonathan, Polgar-Turcsanyi, Mariann, Saxena, Shrishti, Paul, Anu, Glanz, Bonnie I., Weiner, Howard L., Chitnis, Tanuja
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330583/
https://www.ncbi.nlm.nih.gov/pubmed/35952457
http://dx.doi.org/10.1016/j.msard.2022.104079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9330583/
https://www.ncbi.nlm.nih.gov/pubmed/35952457
http://dx.doi.org/10.1016/j.msard.2022.104079

Ejemplares similares